Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
12 "Hye Jin Kang"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Hematologic malignancy
Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea
Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee
Cancer Res Treat. 2024;56(2):681-687.   Published online November 10, 2023
DOI: https://doi.org/10.4143/crt.2023.1042
AbstractAbstract PDFPubReaderePub
Purpose
Programmed death-1 blockade with pembrolizumab has shown promising activity in relapsed/refractory (R/R) extranodal natural killer/T-cell lymphoma (NKTCL), but studies are limited, with small patient numbers.
Materials and Methods
Thirteen institutes involved with the Consortium for Improving Survival of Lymphoma, a Korean lymphoma study group, collected the clinical data of 59 patients treated with pembrolizumab as salvage therapy between 2016 and 2022.
Results
The median age of the patients was 60 years (range, 22 to 87 years), and 76.3% had advanced Ann Abor stage disease. Pembrolizumab was given to 35.6%, 40.7%, and 23.7% of the patients as second-, third-, and fourth- or higher-line chemotherapy, respectively. The overall response rate was 40.7%, with 28.8% having complete response. The estimated 2-year progression-free survival (PFS) and overall survival rates for all patients were 21.5% and 28.7%, respectively; for responders, the rates were 53.0% and 60.7%, respectively. Although not statistically significant, Eastern Cooperative Oncology Group performance status ≥ 2 (hazard ratio [HR], 1.91; 95% confidence interval [95% CI], 0.93 to 3.94; p=0.078) and stage III or IV disease (HR, 2.59; 95% CI, 0.96 to 6.96; p=0.060) were associated with a trend toward shorter PFS in multivariate analysis. Grade 3 or 4 adverse events (AEs) were noted in 12 patients (20.3%); neutropenia (10.2%), fatigue (6.8%), and pneumonitis (5.1%) were most common AEs.
Conclusion
In conclusion, while pembrolizumab had a modest effect on patients with R/R NKTCL, it may be a useful salvage therapy for patients with localized disease and good performance status.

Citations

Citations to this article as recorded by  
  • Pembrolizumab

    Reactions Weekly.2024; 2025(1): 390.     CrossRef
  • 3,106 View
  • 187 Download
  • 1 Crossref
Close layer
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
Yu Ri Kim, Jin Seok Kim, Won Seog Kim, Hyeon Seok Eom, Deok-Hwan Yang, Sung Hwa Bae, Hyo Jung Kim, Jae Hoon Lee, Suk-Joong Oh, Sung-Soo Yoon, Jae-Yong Kwak, Chul Won Choi, Min Kyoung Kim, Sung Young Oh, Hye Jin Kang, Seung Hyun Nam, Hyeok Shim, Joon Seong Park, Yeung-Chul Mun, Cheolwon Suh, the Korean Society of Hematology Lymphoma Working Party
Cancer Res Treat. 2023;55(4):1355-1362.   Published online March 30, 2023
DOI: https://doi.org/10.4143/crt.2023.271
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This phase II, open-label, multicenter study aimed to investigate the efficacy and safety of a rituximab intensification for the 1st cycle with every 21-day of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP-21) among patients with previously untreated advanced-stage or bulky diffuse large B-cell lymphoma (DLBCL).
Materials and Methods
Ninety-two patients with stage III/IV or bulky DLBCL from 21 institutions were administered 8 cycles of R-CHOP-21 with an additional one dose of rituximab intensification on day 0 of the 1st cycle (RR-CHOP). The primary endpoint was a complete response (CR) rate after 3 cycles of chemotherapy.
Results
Among the 92 DLBCL patients assessed herein, the response rate after 3 cycles of chemotherapy was 88.0% (38.0% CR+50.0% partial response [PR]). After the completion of 8 cycles of chemotherapy, the overall response rate was observed for 68.4% (58.7% CR+9.8% PR). The 3-year progression-free survival rate was 64.0%, and the 3-year overall survival rate was 70.4%. Febrile neutropenia was one of the most frequent grade 3 adverse events (40.0%) and 5 treatment-related deaths occurred. Compared with the clinical outcomes of patients who received R-CHOP chemotherapy as a historical control, the interim CR rate was higher in male patients with RR-CHOP (20.5% vs. 48.8%, p=0.016).
Conclusion
Rituximab intensification on days 0 to the 1st cycle of the standard 8 cycles R-CHOP-21 for advanced DLBCL yielded favorable response rates after the 3 cycles of chemotherapy and acceptable toxicities, especially for male patients. ClinicalTrials.gov ID: NCT01054781.
  • 3,841 View
  • 247 Download
Close layer
Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
Hyungwoo Cho, Dok Hyun Yoon, Dong-Yeop Shin, Youngil Koh, Sung-Soo Yoon, Seok Jin Kim, Young Rok Do, Gyeong-Won Lee, Jae-Yong Kwak, Yong Park, Min Kyoung Kim, Hye Jin Kang, Jun Ho Yi, Kwai Han Yoo, Won Sik Lee, Byeong Bae Park, Jae Cheol Jo, Hyeon-Seok Eom, Hyo Jung Kim, Seong Hyun Jeong, Young-Woong Won, Byeong Seok Sohn, Ji-Hyun Kwon, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2023;55(2):684-692.   Published online January 2, 2023
DOI: https://doi.org/10.4143/crt.2022.1434
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients.
Materials and Methods
Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. All patients were pathologically diagnosed with PTCL.
Results
A total of 191 patients with PTCL were enrolled in this prospective registry study. PTCL, not otherwise specified (PTCL-NOS) was the most common pathologic subtype (n=80, 41.9%), followed by angioimmunoblastic T-cell lymphoma (AITL) (n=60, 31.4%). With a median follow-up duration of 3.9 years, the 3-year progression-free survival (PFS) and overall survival (OS) rates were 39.5% and 60.4%, respectively. The role of upfront ASCT was evaluated in patients who were considered transplant-eligible (n=59). ASCT was performed as an upfront consolidative treatment in 32 (54.2%) of these patients. There were no significant differences in PFS and OS between the ASCT and non-ASCT groups for all patients (n=59) and for patients with PTCL-NOS (n=26). However, in patients with AITL, the ASCT group was associated with significantly better PFS than the non-ASCT group, although there was no significant difference in OS.
Conclusion
The current study demonstrated that the survival outcomes with the current treatment options remain poor for patients with PTCL-NOS. Upfront ASCT may provide a survival benefit for patients with AITL, but not PTCL-NOS.

Citations

Citations to this article as recorded by  
  • Successful Treatment, with Chemotherapy and Intravenous Administration of Ascorbic Acid, of a Patient with Peripheral T-Cell Lymphoma, Not Otherwise Specified
    Chiaki Tokoro, Atsushi Tashiro, Kenji Ina, Yoshiteru Tanaka, Hiroyuki Kobayakawa, Takashi Yoshida, Satoshi Kayukawa
    Journal of Cancer Research Updates.2024; 13: 1.     CrossRef
  • Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis
    L. Girard, Y. J. Koh, L. P. Koh, Y. L. Chee, H. L. Chan, J. Lee, S. de Mel, L. M. Poon, M. Samuel
    Bone Marrow Transplantation.2024; 59(6): 838.     CrossRef
  • Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
    Luís Alberto de Pádua Covas Lage, Hebert Fabricio Culler, Cadiele Oliana Reichert, Sheila Aparecida Coelho da Siqueira, Juliana Pereira
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma
    Qingyang Zhang, Le Yin, Qinqiao Lai, Yan Zhao, Hongling Peng
    Clinical and Experimental Medicine.2023; 23(8): 4219.     CrossRef
  • 4,902 View
  • 193 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2023;55(1):325-333.   Published online April 22, 2022
DOI: https://doi.org/10.4143/crt.2022.008
AbstractAbstract PDFPubReaderePub
Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.

Citations

Citations to this article as recorded by  
  • Recent advances in cellular immunotherapy for lymphoid malignancies
    Haerim Chung, Hyunsoo Cho
    Blood Research.2023; 58(4): 166.     CrossRef
  • Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
    Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
    Biomedicine & Pharmacotherapy.2022; 153: 113341.     CrossRef
  • 6,584 View
  • 337 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)
Kyoung Ha Kim, Jae Hoon Lee, Mark Lee, Hoon-Gu Kim, Young Rok Do, Yong Park, Sung Yong Oh, Ho-Jin Shin, Won Seog Kim, Seong Kyu Park, Jee Hyun Kong, Moo-Rim Park, Deok-Hwan Yang, Jae-Yong Kwak, Hye Jin Kang, Yeung-Chul Mun, Jong-Ho Won
Cancer Res Treat. 2023;55(1):304-313.   Published online March 30, 2022
DOI: https://doi.org/10.4143/crt.2022.004
AbstractAbstract PDFPubReaderePub
Purpose
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin’s lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning regimen was effective in patients with relapsed or high-risk NHL. Moreover, the busulfan, cyclophosphamide, and etoposide (BuCE) conditioning regimen has been used widely in ASCT for NHL. Therefore, based on these encouraging results, this randomized phase II multicenter trial compared the outcomes of BuME and BuCE as conditioning therapies for ASCT in patients with NHL.
Materials and Methods
Patients were randomly assigned to receive either BuME (n=36) or BuCE (n=39). The BuME regimen was comprised of busulfan (3.2 mg/kg/day, intravenously) administered on days –7, –6, and –5, etoposide (400 mg/m2 intravenously) on days –5 and –4, and melphalan (50 mg/m2/day intravenously) on days –3 and –2. The BuCE regimen was comprised of busulfan (3.2 mg/kg/day intravenously) on days –7, –6, and –5, etoposide (400 mg/m2/day intravenously) on days –5 and –4, and cyclophosphamide (50 mg/kg/day intravenously) on days –3 and –2. The primary endpoint was 2-year progression-free survival (PFS).
Results
Seventy-five patients were enrolled. Eleven patients (30.5%) in the BuME group and 13 patients (33.3%) in the BuCE group had disease progression or died. The 2-year PFS rate was 65.4% in the BuME group and 60.6% in the BuCE group (p=0.746). There were no non-relapse mortalities within 100 days after transplantation.
Conclusion
There were no significant differences in PFS between the two groups. Therefore, busulfan-based conditioning regimens, BuME and BuCE, may be important treatment substitutes for the BCNU-containing regimens.

Citations

Citations to this article as recorded by  
  • CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-match
    Tao Wang, Ping Liu, Lili Xu, Lei Gao, Xiong Ni, Gusheng Tang, Li Chen, Jie Chen, Libing Wang, Yang Wang, Weijia Fu, Wenqin Yue, Na Liu, Ruobing Li, Guihua Lu, Yanrong Luo, Jianmin Yang
    Annals of Hematology.2024; 103(2): 575.     CrossRef
  • 5,344 View
  • 225 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2022;54(4):1268-1277.   Published online December 30, 2021
DOI: https://doi.org/10.4143/crt.2021.1168
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).
Materials and methods
We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).
Results
Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047).
Conclusion
Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.
  • 7,147 View
  • 285 Download
  • 1 Web of Science
Close layer
Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon-Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo-Ick Yang, Weon Seo Park, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2020;52(2):374-387.   Published online August 13, 2019
DOI: https://doi.org/10.4143/crt.2019.198
AbstractAbstract PDFPubReaderePub
Purpose
The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expression in previous studies enrolling patients with a wide range of CD30 expression level. Thus, this study explored the efficacy of BV in high-CD30–expressing non-Hodgkin lymphoma (NHL) patients most likely to benefit.
Materials and Methods
This phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-CD30–expressing NHL, with BV administered intravenously at 1.8 mg/kg every 3 weeks. The primary endpoint was > 40% disease control rate, consisting of complete response (CR), partial response (PR), or stable disease. We defined high CD30 expression as ≥ 30% tumor cells positive for CD30 by immunohistochemistry.
Results
High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lymphoma. The disease control rate was 48.5% (16/33) including six CR and six PR; six patients (4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and survival were not associated with CD30 expression levels. Over a median of 29.2 months of follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1 months, respectively. The most common adverse events were fever (39%), neutropenia (30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a post-hoc analysis for the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1- negative patients showed a higher response (55.6%, 5/9) than MUM1-positive patients (13.3%, 2/15).
Conclusion
BV performance as a single agent was acceptable in terms of disease control rates and toxicity profiles, especially MUM1-negative patients.

Citations

Citations to this article as recorded by  
  • Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review
    Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi
    Current Cancer Therapy Reviews.2024; 20(1): 53.     CrossRef
  • Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30‐positive cutaneous T‐cell lymphoma
    Yoji Hirai, Jun Sakurai, Shiho Yoshida, Takashi Kikuchi, Toshiharu Mitsuhashi, Tomoko Miyake, Taku Fujimura, Riichiro Abe, Hiroki Fujikawa, Hikari Boki, Hiraku Suga, Sayaka Shibata, Tomomitsu Miyagaki, Takatoshi Shimauchi, Eiji Kiyohara, Yoshio Kawakami,
    The Journal of Dermatology.2024; 51(8): 1037.     CrossRef
  • Brentuximab vedotin therapy followed by autologous peripheral stem cell transplantation as a viable treatment option for an older adult with transformed lymphoma: a case report and literature review
    Jiewen Tan, Jinman Zhong, Wanzhen Hu, Guobiao Wu, Chong Zeng, Dan Xiong
    Journal of International Medical Research.2024;[Epub]     CrossRef
  • Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
    Roxanne C. Jewell, Richard J. Mills, Colm Farrell, Sandra A. G. Visser
    British Journal of Clinical Pharmacology.2024;[Epub]     CrossRef
  • Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma
    Chengji Wang, Liang Wang
    Chinese Medical Journal.2024; 137(19): 2308.     CrossRef
  • Treatment of extranodal NK/T-cell lymphoma: From past to future
    Zheng Yan, Shuna Yao, Zhizhong Wang, Wenping Zhou, Zhihua Yao, Yanyan Liu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma
    Ajay Major, Pierluigi Porcu, Bradley M. Haverkos
    Cancers.2023; 15(5): 1366.     CrossRef
  • Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
    Susan Y. Wu, Penny Q. Fang, Ethan B. Wang, Sairah Ahmed, Madeleine Duvic, Preetesh Jain, Luis E. Malpica Castillo, Ranjit Nair, Raphael E. Steiner, Paolo Strati, Auris O. Huen, Swaminathan P. Iyer, Chelsea C. Pinnix, Bouthaina S. Dabaja, Jillian R. Gunthe
    Advances in Radiation Oncology.2023; 8(6): 101279.     CrossRef
  • Novel target and treatment agents for natural killer/T-cell lymphoma
    Xiao-Peng Tian, Yi Cao, Jun Cai, Yu-Chen Zhang, Qi-Hua Zou, Jin-Ni Wang, Yu Fang, Jia-Hui Wang, Song-Bin Guo, Qing-Qing Cai
    Journal of Hematology & Oncology.2023;[Epub]     CrossRef
  • Treatment‐related adverse events of antibody‐drug conjugates in clinical trials: A systematic review and meta‐analysis
    Jinming Li, Guoshuang Shen, Zhen Liu, Yaobang Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Qiqi Xie, Zitao Li, Zhilin Liu, Yi Zhao, Fei Ma, Xinlan Liu, Zhengbo Xu, Jiuda Zhao
    Cancer Innovation.2023; 2(5): 346.     CrossRef
  • Advances and challenges of immunotherapies in NK/T cell lymphomas
    Ling He, Na Chen, Lei Dai, Xingchen Peng
    iScience.2023; 26(11): 108192.     CrossRef
  • Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
    Xudong Zhang, Honghan Qiao, Xiaofei Chai, Xue Gao, Rongjun Ma, Yufu Li, Zunmin Zhu, Mingzhi Zhang
    Cancer Medicine.2023; 12(24): 21725.     CrossRef
  • A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study
    Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang
    Blood Research.2023; 58(4): 194.     CrossRef
  • Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
    Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
    Diagnostics.2022; 12(2): 409.     CrossRef
  • Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
    Jeffrey P. Ward, Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker-Hapak, Amanda F. Cashen, Nina D. Wagner-Johnston, Kami Maddocks, Matthew Mosior, Mark Foster, Kilannin Krysiak, Alina Schmidt, Zachary L. Skidmore, Sweta Desai, Marcu
    Blood.2022; 139(13): 1999.     CrossRef
  • Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
    Sotirios G. Papageorgiou, Thomas P. Thomopoulos, Athanasios Liaskas, Theodoros P. Vassilakopoulos
    Cancers.2022; 14(8): 1917.     CrossRef
  • Basic immunohistochemistry for lymphoma diagnosis
    Junhun Cho
    Blood Research.2022; 57(S1): S55.     CrossRef
  • Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
    John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
    Journal of Clinical Medicine.2022; 11(10): 2699.     CrossRef
  • CD30 + Primary intestinal T-cell lymphoma (unclassified) masquerading as chronic inflammation: a case report
    Kashif Osmani, Eshana Shah, Bradley Drumheller, Shaun Webb, Manmeet Singh, Paul Rubinstein, John Patrick Galvin, Megan S. Lim, Carlos Murga-Zamalloa
    Diagnostic Pathology.2022;[Epub]     CrossRef
  • EBV-associated NK and T-cell lymphoid neoplasms
    Hiroshi Kimura, Laurence de Leval, Qingqing Cai, Won Seog Kim
    Current Opinion in Oncology.2022; 34(5): 422.     CrossRef
  • Intravascular NK/T-Cell Lymphoma: What We Know about This Diagnostically Challenging, Aggressive Disease
    Magda Zanelli, Paola Parente, Francesca Sanguedolce, Maurizio Zizzo, Andrea Palicelli, Alessandra Bisagni, Illuminato Carosi, Domenico Trombetta, Luca Mastracci, Linda Ricci, Saverio Pancetti, Giovanni Martino, Giuseppe Broggi, Rosario Caltabiano, Alberto
    Cancers.2022; 14(21): 5458.     CrossRef
  • Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
    Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
    Seminars in Hematology.2022; 59(4): 198.     CrossRef
  • Primary Mediastinal B-Cell Lymphoma: Novel Precision Therapies and Future Directions
    Huan Chen, Tao Pan, Yizi He, Ruolan Zeng, Yajun Li, Liming Yi, Hui Zang, Siwei Chen, Qintong Duan, Ling Xiao, Hui Zhou
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • NK-/T-cell lymphomas
    Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang
    Leukemia.2021; 35(9): 2460.     CrossRef
  • The landscape of new drugs in extranodal NK/T-cell lymphoma
    Liang Wang, Lin-Rong Li, Luo Zhang, Jing-Wen Wang
    Cancer Treatment Reviews.2020; 89: 102065.     CrossRef
  • Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma
    Caiqin Xie, Xian Li, Hui Zeng, Wenbin Qian
    Experimental Hematology & Oncology.2020;[Epub]     CrossRef
  • New agents and regimens for diffuse large B cell lymphoma
    Liang Wang, Lin-rong Li, Ken H. Young
    Journal of Hematology & Oncology.2020;[Epub]     CrossRef
  • A Phase II Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive- and CD30-Positive Lymphomas
    Miso Kim, Jeong-Ok Lee, Jiwon Koh, Tae Min Kim, Ji Yun Lee, Yoon Kyung Jeon, Bhumsuk Keam, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heo
    SSRN Electronic Journal .2020;[Epub]     CrossRef
  • 9,511 View
  • 625 Download
  • 29 Web of Science
  • 28 Crossref
Close layer
Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01
Jung Hye Choi, Tae Min Kim, Hyo Jung Kim, Sung Ae Koh, Yeung-Chul Mun, Hye Jin Kang, Yun Hwa Jung, Hyeok Shim, So Young Chong, Der-Sheng Sun, Soonil Lee, Byeong Bae Park, Jung Hye Kwon, Seung-Hyun Nam, Jun Ho Yi, Young Jin Yuh, Jong-Youl Jin, Jae Joon Han, Seok-Hyun Kim
Cancer Res Treat. 2018;50(2):590-598.   Published online June 9, 2017
DOI: https://doi.org/10.4143/crt.2017.172
AbstractAbstract PDFPubReaderePub
Purpose
The treatment strategy for elderly patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) has not been established because of poor treatment tolerability and lack of data.
Materials and Methods
This multicenter retrospective study was conducted to investigate clinical characteristics, treatment patterns and outcomes of patients older than 80 years who were diagnosed with DLBCL at 19 institutions in Korea between 2005 and 2016.
Results
A total of 194 patients were identified (median age, 83.3 years). Of these, 114 patients had an age-adjusted International Prognostic Index (aaIPI) score of 2-3 and 48 had a Charlson index score of 4 or more. R-CHOP was given in 124 cases, R-CVP in 13 cases, other chemotherapy in 17 cases, radiation alone in nine cases, and surgery alone in two cases. Twenty-nine patients did not undergo any treatment. The median number of chemotherapy cycles was three. Only 37 patients completed the planned treatment cycles. The overall response rate from 105 evaluable patientswas 90.5% (complete response, 41.9%). Twentynine patients died due to treatment-related toxicities (TRT). Thirteen patients died due to TRT after the first cycle. Median overall survival was 14.0 months. The main causes of death were disease progression (30.8%) and TRT (27.1%). In multivariate analysis, overall survival was affected by aaIPI, hypoalbuminemia, elevated creatinine, and treatment.
Conclusion
Age itself should not be a contraindication to treatment. However, since elderly patients show higher rates of TRT due to infection, careful monitoring and dose modification of chemotherapeutic agents is needed.

Citations

Citations to this article as recorded by  
  • Treatment Patterns and Costs Among US Patients With Diffuse Large B-Cell Lymphoma not Treated With 2L Stem Cell Transplantation
    Teofilia Acheampong, Tao Gu, Trong Kim Le, Scott J Keating
    Future Oncology.2024; 20(10): 623.     CrossRef
  • TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma
    Will Harris, Edward J. Bataillard, Yoonha Choi, Tarec C. El-Galaly, Vaikunth Cuchelkar, Carsten Henneges, Antonia Kwan, Daniel J. Schneider, Joseph N. Paulson, Tina G. Nielsen
    JCO Clinical Cancer Informatics.2022;[Epub]     CrossRef
  • A Multicenter Study of 239 Patients Aged Over 70 Years With Diffuse Large B-Cell Lymphoma in China
    Chunli Yang, Qiaoer Li, Ke Xie, Yakun Zhang, Dania Xiang, Yunwei Han, Liqun Zou
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B‐cell lymphoma
    Se‐Il Go, Mi Jung Park, Sungwoo Park, Myoung Hee Kang, Hoon‐Gu Kim, Jung Hun Kang, Jung Hoon Kim, Gyeong‐Won Lee
    Journal of Cachexia, Sarcopenia and Muscle.2021; 12(6): 2211.     CrossRef
  • Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma – Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007–2015
    Vicki A. Morrison, Laurie Hamilton, Augustina Ogbonnaya, Aditya Raju, Kristin Hennenfent, Aaron Galaznik
    Journal of Geriatric Oncology.2020; 11(1): 41.     CrossRef
  • Clinical characteristics, treatment patterns and outcomes of patients older than 80 years diagnosed with DLBCL in China over a 10-year period
    Zhan Shi, Xi Tang, Qianwen Shen, Jiayan Chen, Fei Liu, Xi Chen, Jingwen Wang, Jie Zhuang
    Cancer Chemotherapy and Pharmacology.2019; 84(1): 127.     CrossRef
  • Antineoplastics

    Reactions Weekly.2018; 1701(1): 32.     CrossRef
  • 10,520 View
  • 319 Download
  • 7 Web of Science
  • 7 Crossref
Close layer
Review Article
Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
Yoon-Koo Kang, Hye Jin Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
Cancer Res Treat. 2012;44(2):85-96.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.85
AbstractAbstract PDFPubReaderePub
Despite their rarity in incidence and prevalence, gastrointestinal stromal tumors (GISTs) have emerged as a distinct and noteworthy pathogenetic entity. The clinical management of GISTs has rapidly evolved due to the recent elucidation of their oncogenic signal transduction pathway and the introduction of molecular-targeted therapies. Successful management of GISTs requires a multidisciplinary approach firmly based on an accurate histopathologic diagnosis. In 2007, the Korean GIST study group published the first guideline for optimal diagnosis and treatment of GISTs in Korea. The second version of the guideline was published in 2010. Herein, we provide the results of relevant clinical studies for the purpose of further revision to the guideline. We expect this new guideline will enhance the accuracy of diagnosis, as performed by members of the Korean associate of physicians involved in GIST patient care, thus improving the efficacy of treatment.

Citations

Citations to this article as recorded by  
  • Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
    Satish Subbiah Nagaraj, Sriram Deivasigamani, Amresh Aruni, Hemanth Kumar, Anurag Sachan, Jayanta Samanta, Amanjit Bal
    Journal of Gastrointestinal Cancer.2023; 54(1): 316.     CrossRef
  • The Feasibility and Safety of the Clip-and-Snare Method with a Prelooping Technique for Gastric Submucosal Tumors Removal: A Single-Center Experience (with Video)
    Qi Tang, Rui-Yue Shi, Jun Yao, Li-Sheng Wang, De-Feng Li, Alessandro Granito
    Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1.     CrossRef
  • Gastrointestinal stromal tumor of the small intestine of high malignant potential
    Aleksandar Mladenović, Miljan Jovančević, Zoran Milošević
    PONS - medicinski casopis.2022; 19(1): 33.     CrossRef
  • Rare Occurrence of Microsatellite Instability in Gastrointestinal Stromal Tumors
    Joonhong Park, Hae Jung Sul, Jeong Goo Kim
    Medicina.2021; 57(2): 174.     CrossRef
  • The Pathologic Confirmation in Subepithelial Tumors
    Kwan Hong Lee, Chan Kyoo Yoo, Hang Lak Lee, Kang Nyeong Lee, Dae Won Jun, Oh Young Lee, Dong Soo Han, Byung Chul Yoon, Ho Soon Choi, Jai Hoon Yoon
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(3): 215.     CrossRef
  • Diagnosis and Treatment of Duodenal Gastrointestinal Stromal Tumors
    Haojie Du, Longgui Ning, Sha Li, Xinhe Lou, Hongtan Chen, Fengling Hu, Guodong Shan, Fenming Zhang, Guoqiang Xu
    Clinical and Translational Gastroenterology.2020; 11(3): e00156.     CrossRef
  • Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
    Hans Gelderblom, Robin L. Jones, Suzanne George, Claudia Valverde Morales, Charlotte Benson, Jean-Yves Blay, Daniel J. Renouf, Toshihiko Doi, Axel Le Cesne, Michael Leahy, Sabine Hertle, Paola Aimone, Ulrike Brandt, Patrick Schӧffski
    British Journal of Cancer.2020; 122(8): 1158.     CrossRef
  • Life-threatening bleeding with intussusception due to gastrointestinal stromal tumor: a case report
    Min Sung Kim, In Teak Woo, Young Min Jo, Jin Hyung Lee, Byung Sam Park
    Surgical Case Reports.2019;[Epub]     CrossRef
  • Safety profile and oncological outcomes of gastric gastrointestinal stromal tumors (GISTs) robotic resection: Single center experience
    Cristina Maggioni, Atsuo Shida, Raffaello Mancini, Luigi Ioni, Graziano Pernazza
    The International Journal of Medical Robotics and Computer Assisted Surgery.2019;[Epub]     CrossRef
  • A novel technique for removing large gastric subepithelial tumors with ESD method in the subcardia region
    Bingtuan Liu, Han Chen, Weifeng Zhang, Guoxin Zhang
    Oncology Letters.2019;[Epub]     CrossRef
  • Ultrasound-Guided Intraoperative Radiofrequency Ablation and Surgical Resection for Liver Metastasis from Malignant Gastrointestinal Stromal Tumors
    In Sun Yoon, Ji Hoon Shin, Kichang Han, Pyo Nyun Kim, Ki Hun Kim, Yoon-Koo Kang, Heung Kyu Ko
    Korean Journal of Radiology.2018; 19(1): 54.     CrossRef
  • Robotic Gastrotomy With Intracorporeal Suture for Patients With Gastric Gastrointestinal Stromal Tumors Located at Cardia and Subcardiac Region
    Jian Zhao, Gang Wang, Zhiwei Jiang, Chuanwei Jiang, Jiang Liu, Jiahui Zhou, Jieshou Li
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2018; 28(1): e1.     CrossRef
  • A Novel Pathological Prognostic Score (PPS) to Identify “Very High-Risk” Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)
    Xuechao Liu, Haibo Qiu, Zhiming Wu, Peng Zhang, Xingyu Feng, Tao Chen, Yong Li, Kaixiong Tao, Guoxin Li, Xiaowei Sun, Zhiwei Zhou
    Journal of Gastrointestinal Surgery.2018; 22(12): 2150.     CrossRef
  • Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
    Bruno Vincenzi, Margherita Nannini, Giuseppe Badalamenti, Giovanni Grignani, Elena Fumagalli, Silvia Gasperoni, Lorenzo D’Ambrosio, Lorena Incorvaia, Marco Stellato, Mariella Spalato Ceruso, Andrea Napolitano, Sergio Valeri, Daniele Santini, Giuseppe Toni
    Therapeutic Advances in Medical Oncology.2018;[Epub]     CrossRef
  • Current research and treatment for gastrointestinal stromal tumors
    Kheng Tian Lim, Kok Yang Tan
    World Journal of Gastroenterology.2017; 23(27): 4856.     CrossRef
  • Extra-gastrointestinal stromal tumor of the pancreas: report of a case
    Hyung Jun Kwon
    Annals of Hepato-Biliary-Pancreatic Surgery.2017; 21(4): 237.     CrossRef
  • The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
    Toshirou Nishida, Jean-Yves Blay, Seiichi Hirota, Yuko Kitagawa, Yoon-Koo Kang
    Gastric Cancer.2016; 19(1): 3.     CrossRef
  • Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
    Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Mo Youl Beck, In Soon Lee, Mi Jung Choi, Mi Woo Lee, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(1): 162.     CrossRef
  • Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors
    Changhoon Yoo, Min-Hee Ryu, Jungmin Jo, Inkeun Park, Baek-Yeol Ryoo, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(2): 546.     CrossRef
  • Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)
    Changhoon Yoo, Min-Hee Ryu, Byung-Ho Nam, Baek-Yeol Ryoo, George D. Demetri, Yoon-Koo Kang
    European Journal of Cancer.2016; 52: 201.     CrossRef
  • Schwannoma of the stomach: a case report
    Aminder Singh, Ankur Mittal, Bhavna Garg, Neena Sood
    Journal of Medical Case Reports.2016;[Epub]     CrossRef
  • Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
    Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
    Cancer Research and Treatment.2016; 48(4): 1155.     CrossRef
  • Unusual gastroduodenal intussusception secondary to a gastrointestinal stromal tumor of the gastric fundus
    Toshihide Komatsubara, Toru Zuiki, Alan Kawarai Lefor, Norio Hirota, Jun Oki
    International Journal of Surgery Open.2016; 5: 33.     CrossRef
  • Rechallenge with imatinib in advanced gastrointestinal stromal tumors: clinical implications of the RIGHT trial
    Changhoon Yoo, Yoon-Koo Kang
    Clinical Investigation.2015; 5(7): 665.     CrossRef
  • The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
    Seong Joon Park, Min-Hee Ryu, Baek-Yeol Ryoo, Young Soo Park, Byeong Seok Sohn, Hwa Jung Kim, Chan Wook Kim, Ki-Hun Kim, Chang Sik Yu, Jeong Hwan Yook, Byung Sik Kim, Yoon-Koo Kang
    Annals of Surgical Oncology.2014; 21(13): 4211.     CrossRef
  • Minimally invasive surgery for submucosal (subepithelial) tumors of the stomach
    Chang Min Lee
    World Journal of Gastroenterology.2014; 20(36): 13035.     CrossRef
  • Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Y-K Kang, C Yoo, B-Y Ryoo, J J Lee, E Tan, I Park, J H Park, Y J Choi, J Jo, J-S Ryu, M-H Ryu
    British Journal of Cancer.2013; 109(9): 2309.     CrossRef
  • Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
    Yoon-Koo Kang, Min-Hee Ryu, Changhoon Yoo, Baek-Yeol Ryoo, Hyun Jin Kim, Jong Jin Lee, Byung-Ho Nam, Nikhil Ramaiya, Jyothi Jagannathan, George D Demetri
    The Lancet Oncology.2013; 14(12): 1175.     CrossRef
  • Surgeon's role for gastric gastrointestinal stromal tumor in imatinib era
    Ji Yeon Park, Young-Woo Kim
    Korean Journal of Clinical Oncology.2013; 9(1): 5.     CrossRef
  • Diagnosis and Treatment of Gastrointestinal Stromal Tumor
    Yoon-Koo Kang, Dong Hoe Koo
    Korean Journal of Medicine.2013; 85(4): 341.     CrossRef
  • Surgical Treatment of Gastric Gastrointestinal Stromal Tumor
    Seong-Ho Kong, Han-Kwang Yang
    Journal of Gastric Cancer.2013; 13(1): 3.     CrossRef
  • Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan
    Chun-Nan Yeh, Tsann-Long Hwang, Ching-Shui Huang, Po-Huang Lee, Chew-Wun Wu, Ker Chen-Guo, Yi-Yin Jan, Miin-Fu Chen
    World Journal of Surgical Oncology.2012;[Epub]     CrossRef
  • 51,077 View
  • 133 Download
  • 32 Crossref
Close layer
Case Report
Primary Gastric Choriocarcinoma: Two Case Reports and Review of the Literatures
Jung Ho Yoon, Min Soo Kim, Eun Hee Kook, Se Han Ahn, Se Young Jeong, Min Sung Han, Jung Kwon Huh, Hye Jin Kang, Im Il Na, Soo Youn Cho, Sang Bum Kim, Baek Yeol Ryoo, Sung Hyun Yang
Cancer Res Treat. 2008;40(3):145-150.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.145
AbstractAbstract PDFPubReaderePub

Primary gastric choriocarcinoma (PGC) is a rare tumor, and its pathogenesis is still uncertain. Most PGCs have been reported to possess an adenocarcinoma component of variable extent, and pure PGC is especially rare. The diagnosis of PGC is confirmed by exhibition of choriocarcinomatous components on biopsy and exhibition of β-hCG positive cell on immunohistochemical stain and elevation of the serum β-hCG. Moreover it must be confirmed that no other site including gonads displays any tumor masses. The PGC tends to be more invasive and to have early metastasis. The median survival is known to be less than several months. We report two cases. The first case was a 62 year-old man who was diagnosed as advanced gastric cancer (AGC) by endoscopic biopsy with hepatic metasasis and received palliative chemotherapy with modified FOLFOX regimen and Genexol plus cisplatin regimen. He underwent subtotal gastrectomy due to perforation of the stomach during chemotherapy. On post-operative biopsy, He was re-diagnosed as PGC and received another palliative chemotherapy modified FOLFIRI, BEP, EMACO, VIP. However, multiple liver metastases were aggravated, and also serum AFP level increased. Ultimately, the paient died 10 months after initial diagnosis. Another case was a 45 year-old man. On endoscopic biopsy, he was diagnosed as AGC of adenocarcinoma. On Chest and Abdomen CT, multiple pulmonary and hepatic metastasis were also confirmed. On liver biopsy, He was diagnosed as PGC. The immunohistochemical stains were performed and the results were cytokeratin positive, EMA negative and β-hCG weak positive. The serum β-hCG level was highly elevated. BEP, VIP and EMA/CO combination therapy were administered, but he died at 12th months after the initial diagnosis.

Citations

Citations to this article as recorded by  
  • Morphological and molecular pathological features of the breast carcinoma with choriocarcinomatous features: A case report and a literature review
    Jingchun Xu, Yi Xu, Cheng Xu, Cong Wang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Case Report: a rare primary gastric choriocarcinoma revealed on 18F-FDG PET/CT
    Yi Zhao, Wei Diao, Suping Li, Mengxi Yang, Zhuzhong Cheng
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Severe thyrotoxicosis as initial presentation of gastric choriocarcinoma: a case report
    Nicole M. Iñiguez-Ariza, Dalia Cuenca, Juvenal Franco-Granillo, Alberto Villalobos-Prieto, Janet Pineda-Díaz, Javier Baquera-Heredia
    Journal of Medical Case Reports.2022;[Epub]     CrossRef
  • Primary gastric choriocarcinoma: A case report
    Zhang Xusheng, Yan Yuke, Meng Yun, Guo Huijun, Peng Jiangshan, Du Xueqin, Yang Xiaojun
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Successful treatment of a high-risk nonseminomatous germ cell tumor using etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine: A case report
    Jina Yun, Sang W Lee, Sung H Lim, Se H Kim, Chan K Kim, Seong K Park
    World Journal of Clinical Cases.2020; 8(21): 5334.     CrossRef
  • Primary Gastric Choriocarcinoma Coexisting with Adenocarcinoma
    Joo Hyun Lee, Jeong Kyun Lee, Dong Baek Kang
    The Korean Journal of Gastroenterology.2019; 73(6): 350.     CrossRef
  • Primary gastric choriocarcinoma with multiple metastases – A case report and literature review of carcinogenesis
    Yiqin Xiong, Michelle X. Yang
    Human Pathology: Case Reports.2019; 18: 200330.     CrossRef
  • Collision tumor of choriocarcinoma and small cell carcinoma of the stomach: A case report
    Shuichi Fukuda, Yoshinori Fujiwara, Tomoko Wakasa, Keisuke Inoue, Kotaro Kitani, Hajime Ishikawa, Masanori Tsujie, Masao Yukawa, Yoshio Ohta, Masatoshi Inoue
    International Journal of Surgery Case Reports.2017; 37: 216.     CrossRef
  • Primary Choriocarcinoma of the Stomach. A Case Report and Review of the Literature
    Rahul Raghavapuram, Fadl H Veerankutty, M Anandakumar
    Indian Journal of Surgical Oncology.2016; 7(1): 119.     CrossRef
  • A Case of a Duodenal Papilla Adenosquamous Carcinoma with Trophoblastic Differentiation
    Daichi KITAGUCHI, Shingo SAKASHITA, Shinji HASHIMOTO, Tatsuya ODA, Nobuhiro OHKOHCHI, Masayuki NOGUCHI
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2016; 77(6): 1440.     CrossRef
  • Biochemical remission by chemoradiotherapy in male mediastinal choriocarcinoma with diffuse lung metastasis: A case report
    JING ZHANG, ZHI-JUN WANG, BIN YANG, YOU-YING WEI, LING YANG, YANG HU, YAN-PING HU
    Oncology Letters.2016; 11(4): 2615.     CrossRef
  • Primary gastric choriocarcinoma: A rare case
    Vilma Florença Martins, Filipa Moreno, J. Ramón Vizcaíno, Jorge Santos
    International Journal of Surgery Case Reports.2015; 14: 44.     CrossRef
  • Resectable Primary Gastric Choriocarcinoma with Solitary Synchronous Liver Metastasis
    Masafumi Tomita, Eisei Nishino, Tomoya Takami, Yu Oshima, Kotaro Hatano, Satoshi Wakama, Hayato Furue, Yasuhiro Matsuda, Naoki Kataoka, Tomoyuki Yamaguchi
    The Japanese Journal of Gastroenterological Surgery.2015; 48(6): 488.     CrossRef
  • Endometrioid adenocarcinoma with choriocarcinomatous differentiation: A case report and review of the literature
    MITSUAKI ISHIDA, HIDETOSHI OKABE
    Oncology Letters.2013; 6(3): 655.     CrossRef
  • Gastric adenocarcinoma with choriocarcinomatous and hepatoid differentiation
    Seong Wook Hwang, Sun Jae Lee, Po Eun Park, Mee Seon Kim, Han‐Ik Bae
    Basic and Applied Pathology.2012; 5(1): 22.     CrossRef
  • Pathological Complete Response and Two-year Disease-free Survival in a Primary Gastric Choriocarcinoma Patient with Advanced Liver Metastases Treated with Germ Cell Tumor-based Chemotherapy: A Case Report
    Y. Waseda, Y. Komai, A. Yano, Y. Fujii, N. Noguchi, K. Kihara
    Japanese Journal of Clinical Oncology.2012; 42(12): 1197.     CrossRef
  • Gastric cancer with choriocarcinoma and yolk sac tumor components: Case report
    Nobuo Satake, Motoya Chikakiyo, Toshiyuki Yagi, Yasuhiro Suzuki, Takanori Hirose
    Pathology International.2011; 61(3): 156.     CrossRef
  • A Coexistent Case of Primary Gastric Choriocarcinoma and Alpha Fetoprotein-producing Gastric Cancer which Caused Rapid Postoperative Progression
    Naoya Sasaki, Yoshiharu Shirakata, Hisashi Shinohara, Kazumi Itoi, Atsuhiko Maki, Yoshifumi Mizuno, Rokuro Mimura, Koushou Takasu
    The Japanese Journal of Gastroenterological Surgery.2011; 44(12): 1535.     CrossRef
  • 11,803 View
  • 62 Download
  • 18 Crossref
Close layer
Original Articles
High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Followed by Autologous Stem-Cell Transplantation for Metastatic Breast Cancer Patients: A 6-Year Follow-Up Result
Hee-Jung Sohn, Sang-Hee Kim, Gyeong-Won Lee, Shin Kim, Hye Jin Kang, Jin-Hee Ahn, Sung-Bae Kim, Sang-We Kim, Woo Kun Kim, Cheolwon Suh
Cancer Res Treat. 2005;37(1):24-30.   Published online February 28, 2005
DOI: https://doi.org/10.4143/crt.2005.37.1.24
AbstractAbstract PDFPubReaderePub
Purpose

The benefit of high-dose chemotherapy (HDC) for metastatic breast cancer (MBC) is controversial. We evaluated the efficacy and safety of HDC with cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation (ASCT) for MBC patients.

Materials and Methods

From September 1994 to December 1999, 23 MBC patients were enrolled. All the patients received 2 to 10 cycles of induction chemotherapy. Before transplantation, 12 patients were in complete response (CR), nine were in partial response (PR), and two had progressive disease (PD). The HDC regimen consisted of cyclophosphamide 1,500 mg/m2/day, thiotepa 125 mg/m2/day and carboplatin 200 mg/m2/day intravenously for 4 consecutive days.

Results

After ASCT, 13 patients (56%) had a CR, five (22%) had a PR, three (13%) had no change, while two (9%) showed a PD. Seventeen patients relapsed or progressed during the median follow-up of 78 months. The median progression-free survival (PFS) time was 11 months and the median overall survival (OS) time was 23 months. The 5-year PFS and OS rates were 22% and 25%, respectively. On the multivariate analyses, less than 4 involved lymph nodes was predictive of a better PFS and OS.

Conclusion

HDC with CTCb for MBC has acceptable toxicity; however, this treatment does not show a survival benefit.

Citations

Citations to this article as recorded by  
  • Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period
    Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Jung Sun Park, Cheolwon Suh
    The Korean Journal of Medicine.2021; 96(6): 501.     CrossRef
  • 8,931 View
  • 48 Download
  • 1 Crossref
Close layer
Concurrent Etoposide/Cisplatin Combination Chemotherapy (EP) and Thoracic Radiotherapy after Two Cycles of EP for Limited Stage Small Cell Lung Cancer
Hee Jung Sohn, Sang We Kim, Jin Hee Ahn, Hye Jin Kang, Sarah Park, Heon Nyoung Jung, Cheol Won Suh, Woo Kun Kim, Sang Wook Lee, Eun Kyung Choi, Sang Do Lee, Woo Sung Kim, Dong Sun Kim, Won Dong Kim, Jung Shin Lee
Cancer Res Treat. 2002;34(6):409-415.   Published online December 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.6.409
AbstractAbstract PDF
Purpose
s: Although the standard management of limited stage small cell lung cancer is concurrent platinum-based chemotherapy with thoracic radiotherapy (TRT), the optimal timing of the TRT remains controversial. We investigated the feasibility of concurrent chemoradiation for the patients with limited stage small cell lung cancer after 2 cycles of combination chemotherapy with Etoposide/Cisplatin (EP).
MATERIALS AND METHODS
EP consisted of Etoposide 100 mg/m2 on day 1 to 3 and Cisplatin 70 mg/m2 on day 1. Six cycles were given to the responders every 4 weeks. Total 55 Gy (1.8 Gy once-daily or 1.2 Gy twice-daily, 5 days per week) of TRT were given to the patients who showed at least a partial response after 2 cycles of EP. The other patients were treated by the physician's decision. The patients with complete remission were recommended to receive prophylactic cranial irradiation.
RESULTS
Fifty patients were enrolled. Thirty-five (70%) of them showed responses (2 complete remissions and 33 partial remissions) after 2 cycles of EP. Thirty-three of the responders were given TRT starting with the 3rd cycle of EP. The nonresponders were treated with salvage chemotherapy and TRT. After completion of treatment for 50 patients, the overall response rate was 86% (29 complete remissions, 14 partial remissions). One patient (2%) showed stable disease, and 6 (12%) showed a progressive disease. The median progression free survival was 326 days and the median survival time was 410 days. One-, 2-, 3-, 4- and 5-year survival rates were 62%, 24%, 14%, 9% and 6%, respectively. As hematologic toxicities during chemoradiation, 35.1% with grade III/IV neutropenia and 18.9% with grade III/IV thrombocytopenia were noted. Grade II/III radiation pneumonitis and radiation esophagitis were noted in 5/1 and 13/1 patients (15.2%/ 3.0% and 39.4%/3.0%), respectively. One patient died of septicemia during chemoradiation.
CONCLUSION
The concurrent EP and TRT after 2 cycles of EP was feasible in limited stage small cell lung cancer. Further study is required for the indentification of optimum timing of TRT during combination chemotherapy.

Citations

Citations to this article as recorded by  
  • Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer
    In-Bong Ha, Bae-Kwon Jeong, Hojin Jeong, Hoon-Sik Choi, Gyu-Young Chai, Myoung-Hee Kang, Hoon Gu Kim, Gyeong-Won Lee, Jae-Beom Na, Ki-Mun Kang
    Radiation Oncology Journal.2013; 31(4): 185.     CrossRef
  • 5,536 View
  • 32 Download
  • 1 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP